Utilization of an Alternative Open Reading Frame of a Normal Gene in Generating a Novel Human Cancer Antigen

By Rong-Fu Wang, Maria R. Parkhurst, Yutaka Kawakami, Paul F. Robbins, and Steven A. Rosenberg

From the Surgery Branch, National Cancer Institute, Bethesda, Maryland 20892

Summary

Tumor infiltrating lymphocytes (TILs) derived from tumor-bearing patients recognize tumor-associated antigens presented by major histocompatibility complex (MHC) class I molecules. The infusion of TIL586 along with interleukin (IL) 2 into an autologous patient with metastatic melanoma resulted in the objective regression of tumor. A gene encoding a tumor antigen recognized by TIL586 was recently isolated and shown to encode gp75. Here we report that an antigenic peptide, MSLQRQFLI:k, recognized by TIL586 was not derived from the normal gp75 protein. Instead, this nonamer peptide resulted from translation of an alternative open reading frame of the same gene. Thus, the gp75 gene encodes two completely different polypeptides, gp75 as an antigen recognized by immunoglobulin G antibodies in sera from a patient with cancer, and a 24-amino acid product as a tumor rejection antigen recognized by T cells. This represents the first demonstration that a human tumor rejection antigen can be generated from a normal cellular gene using an open reading frame other than that used to encode the normal protein. These findings revealed a novel mechanism for generating tumor antigens, which may be useful as vaccines to induce tumor-specific cell-mediated immunity against cancer.

The adoptive transfer of tumor infiltrating lymphocytes (TILs) can mediate tumor regression in patients with metastatic melanoma (1, 2), suggesting that tumor rejection antigens recognized by T cells exist on these tumor cells. The availability of such T cells has made it possible to clone and sequence the genes that encode human melanoma antigens (3–7). The antigens identified so far from human melanoma can be divided into two classes based on their expression pattern. The antigens of the first class are encoded by genes that are expressed only in tumor and testis, but not other normal human tissues. MAGE1, MAGE3, and BAGE are examples of this class (8–10). The second class of antigens represents differentiation antigens encoded by genes that are expressed only in melanocytes, melanomas, and retina. MART-1/Melan-A, gp100, and tyrosinase are examples of this class (11–16). All these antigens are nonmutated self-proteins. Identification of the antigenic epitopes recognized by T cells derived from the corresponding gene products is important not only for understanding the mechanism of immune response to self-antigens, but also for developing new, effective immunotherapeutic strategies with these antigens or synthetic peptides for the treatment of patients with cancer.

Previous studies showed that the infusion of TIL586 plus IL-2 into an autologous patient with melanoma resulted in the objective regression of metastases (17). More recently, we cloned the gene TRP-1, or gp75, encoding the tumor antigen recognized by TIL586 in association with HLA-A31 (18). Interestingly, the gene product, gp75, was originally identified as an antigen recognized by IgG antibodies in the serum from a patient with metastatic melanoma (19). The gene was found to be expressed only in melanoma, normal melanocyte cell lines, and retina, but not in other normal tissues tested (18, 20). Therefore, this gene is a member of the second class of antigens including MART-1/Melan-A, gp100, and tyrosinase.

In this study we report the identification of the antigenic epitope from the TRP-1 gene. ExoIII/S1 deletion analysis allowed us to localize the epitope in a small DNA fragment but failed to identify the epitope from the normal gp75 protein using synthetic peptides. Surprisingly, the peptide recognized by TIL586 was derived from the gene product translated from an alternative open reading frame of the same gene. Substitution of the ATG start codon of this short open reading frame with ATC at nucleotides 294–296 resulted in a complete loss of the ability to stimulate cytokine release from TIL586. Cold-target inhibition ex-
periments indicated that the identified epitope was capable of competing for T cell recognition with a naturally processed peptide present on the tumor cells. Six T cell clones generated from the TIL586 cell line were capable of recognizing 586mel tumor cells, 586EBV B cells pulsed with this peptide, and normal melanocytes in an HLA-A31–restricted fashion, also suggesting that the gene product encoded by the alternative open reading frame might be present in the tumor cells as well as the normal melanocytes. The biological significance and the mechanism by which the overlapping open reading frames are translated from a single cellular gene are discussed.

Materials and Methods

Chemicals and Reagents. The following chemicals and reagents were purchased from the sources indicated: RPMI 1640, AIM-V media, lipofectamine, G418 (GIBCO BRL, Gaithersburg, MD); the eukaryotic expression vector pCR3 (Invitrogen, San Diego, CA); anti–HLA-A31 mAb (One lambda, Canoga Park, CA); anti-IgM antibody conjugated with FITC (Vector Laboratories, Inc., Burlington, CA).

CTLS and Cell Lines. TIL586 were isolated from the tumor specimen of a patient with metastatic melanoma and grown in medium containing IL-2 (6,000 IU/ml) (Cetus Corp., Emoryville, CA) for 32–60 d as previously described (17). TIL586 were predominantly CD8+ T cells. TIL1200 were grown under the same conditions as described for TIL586. The T cell clones were generated by the limiting dilution method from the TIL586 cell line, and then they were expanded in AIM-V medium containing 6,000 IU/ml IL-2.

Melanoma cell lines 397mel, 397mel/A31, 586mel, 624mel, and EBV–transformed B cell lines 586EBV and 1510EBV were established in this laboratory and cultured in ILPMI 1640 medium containing 120 IU/ml of IL-2. After 18–24 h incubation, the cells were washed again, counted, and then mixed with TIL586 at the indicated E/T ratio. Chromium release was measured after 4 h incubation. The peptides were synthesized by a solid-phase method using a peptide synthesizer (model AMS 422; Gilson Co., Inc., Worthington, OH). Some peptides were purified by HPLC and were >98% pure. For titration of the ORF3 peptide recognized by TIL586, 586EBV B cells were incubated with various concentrations of the purified ORF3 peptide. Percentage of specific lysis was determined from the equation (A – B)/(C – B) × 100, where A is lysis of 586EBV B cells by TIL586 in the presence of a peptide, B is spontaneous release from 586EBV B cells in the presence of the same peptide but in the absence of effector cells, and C is the maximum chromium release. Cold-target inhibition of cytolysis was performed using 51Cr–labeled 586mel or 624mel cells as “hot” targets and 586EBV B and T2 cells pulsed with peptides as “cold” targets.

Site-directed Mutagenesis. For carrying out site-directed mutagenesis, we used mutated primers GPMUT1 (5'-GCCATGGGCCAGAGATGATCGGGGAGGTCTGG), GPE2 (5'-GAATTCGAC- TGT CCTGAGAAATTGCCGTTG), GPE1 (5'-GAATTCGTTGAGATGATCGGGGAGGTCTGG), GPMUT1 (5'-GGATCTCGGGCAGGAGATCCTCGGCCCTTGCTTCTCGTGTGCTCCTGAGAAATTGCCGTTG), and GPE2 (5'-GAATTCGAC-TATGAGAACCCTCTGTGCACTGGCCGCTTCTTTTC) to generate a PCR fragment containing a mutation (G to C) at nucleotide 296. The wild-type DNA fragments were amplified by the use of primers GPF (5'-GAAGATCTCGCAATTGCGGAGGTTGAGATCCTCGGCCCTTGCTTCTCGTGTGCTCCTGAGAAATTGCCGTTG), GPE (5'-GAATTCGATCGGGCAGGAGATCCTCGGCCCTTGCTTCTTTTC). To identify the antigenic epitope, we chose the pcDNA776 construct as a starting material for deletion studies. This clone, which was initially identified by a library screening, conferred the ability to stimulate cytokine release from TIL586. Since the goal of this study...
was to identify the epitope recognized by TIL586, we used fragments of the truncated form of gp75, instead of full-length cDNA so that we could quickly locate the epitope in a relatively small DNA fragment. These deletion constructs were then transfected into COS-7 cells together with the pBK-CMV plasmid containing the HLA-A31 gene (18). After 24 h, the transfected COS-7 cells were tested to determine which construct could stimulate cytokine release by TIL586. A small truncated DNA fragment ranging from nucleotide 247 to 771, which lacked the normal gp75 initiation codon, retained the ability to stimulate GM-CSF release by TIL586, suggesting that the epitope recognized by TIL586 was located in the DNA fragment containing nucleotides from 247 to 771. Since there is an ATG start codon in a relatively good context of Kozak sequence (GATATGG) located at nucleotides 445–447 and in the same frame as gp75 open reading frame, we reasoned that the epitope recognized by TIL586 might be located in the region from nucleotide 445 to 771. Therefore, we constructed pPCR210 and pPCR220, which were derivatives of the pCR3 expression vector and contained an internal ATG codon in frame with gp75 (GATATGG) located at 445 bp as a start codon for translation of the truncated normal gp75 protein. However, neither pPCR210 nor pPCR220 conferred the ability to stimulate cytokine secretion from TIL586 after cotransfection of COS-7 with the HLA-A31 gene (Fig. 1 B), suggesting that the epitope was located upstream of these fragments. Therefore, an additional plasmid pD776A was constructed that contained the nucleotide sequence from 247 to 442 and did not have any ATG codon in the same frame as gp75, but did contain two ATG codons in different open reading frames relative to gp75. Surprisingly, this plasmid strongly stimulated cytokine release from TIL586 when cotransfected with A31 cDNA into COS-7 cells. The plasmid pPCR110 containing the authentic start codon of gp75 stimulated severalfold lower cytokine release than did pDel 5 or pD776A when cotransfected with the HLA-A31 gene (Fig. 1 B). These results suggested that the epitope(s) recognized by TIL586 were located in the region from nucleotides 247 to 442.

Although this region (nucleotides 247–442) did not have any ATG start codon in the normal gp75 open reading frame, initiation of translation from non-ATG codons such as ACG, CTG, and GTG had been reported in some cases (21–23). To identify the epitope in this region, we made synthetic peptides based on the peptide binding motif of HLA-A31 (hydrophobic residue at position 2 and positively charged residue at the COOH terminus) (Fig. 2) (24). The majority of the peptides selected for this study were nonamers, although some were 10mers and 11mers. We pulsed these peptides onto 586EBV B cells and tested the ability of these cells to stimulate cytokine release by TIL586 (Table 1). One peptide, AACDQTVLVRR, very weakly induced GM-CSF release from TIL586. However, this peptide failed to sensitize peptide-loaded 586EBV B cells for lysis by TIL586 (Table 1). Because this peptide weakly stimulated cytokine release from TIL586 only when incubated with 586EBV B cells at high concentrations (>1 μg/ml) and did not sensitize the target cells for lysis by TIL586 even at 10 μg/ml of peptide concentration (data not shown), it may not represent the predominant T cell epitope recognized by TIL586.

To further define the region containing the predominant T cell epitope, we constructed two additional plasmids containing PCR DNA fragments amplified by primers GP1F1, GEP1, and GEP2, respectively (Fig. 3 A). As shown in Fig. 3 B, both plasmids conferred the ability to stimulate cytokine release by TIL586 in association with HLA-A31, suggest-
Figure 2. The nucleotide, amino acid sequence, and open reading frames of the gp75 gene. The partial nucleotide and amino acid sequences of the first 157 amino acids were shown from the start codon for translation of ORF1 (gp75). The DNA fragment that conferred the ability to stimulate GM-CSF release from TIL586 is underlined. Two putative start codons, ATG (254-256) and ATG (294-296), are in bold and may result in the translation of ORF2 and ORF3, respectively. The peptide sequence recognized by TIL586 from ORF3 is in bold and underlined.

Antigenic Peptides Resulted from Translation of an Alternative Open Reading Frame of the gp75 Gene. The failure to identify an epitope recognized by TIL586 in this small region suggested to us that alternative open reading frames might be translated. Two ATG codons in the relatively good context were present in this region (nucleotides 247–442) in different open reading frames from ORF1 (Fig. 2). Translation from the first ATG (251 GAGATGA257) resulted in an open reading frame encoding 45 amino acids open reading frame 2 (ORF2), whereas translation starting from the ATG located between nucleotides 294 and 296 (GACATGT) generated a 24–amino acid gene product open reading frame 3 (ORF3) (Fig. 2). Three peptides derived from ORF2 and two peptides from ORF3 were selected and synthesized on the basis of the HLA-A31 binding motif (Table 2 and Fig. 2). Surprisingly, one peptide, MSLQRQFLR (designated as ORF3P), which derived from ORF3, was strongly recognized by TIL586 when pulsed onto 586EBV B cells (Table 2). The recognition of the ORF3P peptide (MSLQRQFLR) by TIL586 was observed only when the peptide was pulsed onto autologous 586EBV B cells and 1510EBV B (A31 +) cells, but not when peptide was loaded onto T2 (non-HLA-A31) cells (Fig. 4A), suggesting that recognition of this peptide by TIL586 was HLA-A31 restricted. The peptide mass of ORF3P was confirmed by mass spectrometry. As shown in Fig. 4B,
TIL586 lysed 586EBV B cells pulsed with the ORF3P peptide, but failed to lyse 586EBV B cells pulsed with an irrelevant peptide, which met the criterion of the peptide-binding motif of HLA-A31 or T2 cells pulsed with the peptide, but failed to lyse 586EBV B cells pulsed with an irrelevant peptide or T2 cells pulsed with the ORF3P peptide but not by 586EBV B cells pulsed with irrelevant peptide or T2 cells pulsed with the ORF3P peptide (Fig. 5 A), indicating that this peptide epitope was capable of competing with a naturally processed peptide on tumor cells for T cell recognition. As predicted, the ORF3P-loaded 586EBV B cells did not inhibit lysis of target 624mel by TIL1200, which recognizes the gp100 antigen in the HLA-A2 context, compared with 586EBV B alone (Fig. 5 B). To further test if T cell clones can recognize both the ORF3P peptide–pulsed 586EBV B cells and tumor cell lines, T cell clones were generated from the TIL586 cell line by limiting dilution (1 cell/well in 96-well round bottom microplate) and further expanded in culture. Six T cell clones were capable of recognizing 586mel tumor cells, 586EBV (294–297) to ATCT (294–297) to eliminate the translation of ORF3, which would result in a change of Cys (UGU) to Ser (UCU) in ORF1 (gp75) (Fig. 3 A). A plasmid containing the mutated gene (pGFMUT1) was tested for its ability to confer recognition by TIL586 when cotransfected into COS-7 along with the HLA-A31 cDNA. Fig. 3 B showed that the mutated gene completely lost the ability to stimulate GM-CSF release by TIL586. This observation indicated that ATG in ORF3 in nucleotide positions 294–296 was required for translation of the 24-amino acid product, and therefore was essential for generating the T cell epitope recognized by TIL586.

Since the Met (ATG) is in position 1 of the peptide epitope, and the mutation of ATG to ATC at nucleotides 294–296 resulted in a change of Met to Ile in position 1 of the peptide, we further investigated the possibility that the loss of recognition of the mutated gene by TIL586 could be due to the loss of the ability of the mutated peptide to bind to MHC class I molecules. A synthetic peptide (ISLQRQFLR) with the same amino acid sequence as that encoded by the mutated gene was made and tested for recognition by TIL586. It was found that the synthetic mutated peptide was still recognized by TIL586 at concentrations comparable to that of the wild-type peptide (data not shown). Furthermore, when the same mutation was introduced into the full-length cDNA, no reactivity to TIL586 was observed, whereas the wild-type cDNA was capable of stimulating cytokine release from TIL586 at a level similar to pPCR-110 (data not shown). This is in agreement with the deletion data, indicating that TIL586 did not recognize peptide(s) in other regions of the gene. These results suggested that the loss of recognition of the mutated gene containing an ATG to ATC substitution at nucleotides 294–296 by T cells was due to inhibition of translation initiation of ORF3.

Recognition of the Antigenic Peptide on Tumor Cells As Well As Melanocytes. To address the question of whether TIL586 recognized a naturally processed peptide similar or identical to the ORF3P peptide on the tumor cells, we examined the ability of the ORF3P peptide–pulsed 586EBV B cells to inhibit lysis of 51Cr-labeled 586mel in a cold-target inhibition assay. Significant inhibition of lysis of 51Cr-labeled 586mel was observed by 586EBV B cells pulsed with the ORF3P peptide but not by 586EBV B cells pulsed with irrelevant peptide or T2 cells pulsed with the ORF3P peptide (Fig. 5 A), indicating that this peptide epitope was capable of competing with a naturally processed peptide on tumor cells for T cell recognition. As predicted, the ORF3P-loaded 586EBV B cells did not inhibit lysis of target 624mel by TIL1200, which recognizes the gp100 antigen in the HLA-A2 context, compared with 586EBV B alone (Fig. 5 B). To further test if T cell clones can recognize both the ORF3P peptide–pulsed 586EBV B cells and tumor cell lines, T cell clones were generated from the TIL586 cell line by limiting dilution (1 cell/well in 96-well round bottom microplate) and further expanded in culture. Six T cell clones were capable of recognizing 586mel tumor cells, 586EBV

Figure 3. An antigenic peptide and translation of an alternative open reading frame. (A) Location and length of PCR fragments amplified by PCR. DNA fragments were obtained by PCR amplification and were then cloned into the pCR3 expression vector. Substitution of ATG at positions 294-296 with ATC was made as described in Materials and Methods. (B) Test of DNA fragments and mutation constructs to stimulate cytokine release from TIL586. GM-CSF release assay was done as in Fig. 1.
proteins, including tyrosinase, gp100, and TRP-2, in the
released GM-CSF release from these clones (data not shown).

**Discussion**

Several antigenic T cell epitopes derived from the normal open reading frame of the corresponding nonmutated shared melanoma antigens such as tyrosinase, MART-1/ Melan-A, and gp100 have been recently identified (16, 25–27). In this study, we demonstrated that the antigenic peptide recognized by TIL586 was derived from a second gene product of the gp75 gene. To our knowledge, this is the first example that T cells recognize an antigenic peptide resulting from the translation of an overlapping open reading frame of the same gene and the only example in eukaryotic cells that two completely different proteins and/or peptides can be translated from overlapping open reading frames of a single cellular gene. The ORF3 of the gp75 gene encodes a short protein of 24 amino acids whose normal function, if any, is unknown. The antigenic peptide recognized by TIL586 is encoded by the sequence located immediately behind the ATG (294–296) start codon of the alternative open reading frame.

Although gp75 shares a 40–45% amino acid sequence identity to tyrosinase, gp100, and TRP-2, cotransfection of HLA-A31 and tyrosinase, gp100, or TRP-2 cDNAs, respectively, into COS-7 cells failed to stimulate GM-CSF release from T cell clones derived from TIL586. A database search did not reveal any proteins that had the HLA-A31 peptide binding motif and significant sequence homology to the peptide epitope recognized by TIL586 and its derived T cell clones. In addition, previous studies showed that melanoma transfectants (gp75+/A31+) conferred the ability to stimulate GM-CSF release from TIL586, but gp75− melanoma transfectants (gp75−/A31+) did not (18). Similar results were obtained with additional melanoma cell lines (gp75−/A31+). These results suggested that it was unlikely that TIL586 recognized the epitope peptide derived from other known genes. Since the ORF3P peptide was the only epitope identified from the gp75 gene and was recognized by six T cell clones derived from TIL586, the peptide may be identical or similar to the naturally processed peptide on tumor cells and melanocytes. This was further supported by cold-target inhibition experiments, since this peptide was capable of competing for T cell rec-

---

**Figure 4.** Characterization of the antigenic peptide recognized by TIL586. (A) GM-CSF release by the HLA-A31-restricted TIL586 when coincubated with various stimulators. Transfection and cytokine assays were performed as in Fig. 1. 586mel and 397mel were included as positive and negative controls for the reactivity of TIL586. The ORF3P peptide was incubated with 586EBV (A31+) and T2 (non-A31) cells at a concentration of 1 μg/ml for 90 min. Stimulation of GM-CSF secretion by TIL586 significantly increased when coincubated with autologous 586EBV and allodemic 1510EBV (A31+) cells pulsed with peptide ORF3P, but not when coincubated with either 586EBV alone or T2 (non-A31) cells loaded with the ORF3P peptide. (B) Cytotoxic lysis of the target cells by TIL586. 586mel (— O——) and 397mel (— □ —) were used as positive and negative controls, respectively. 586EBV B cells were incubated with ORF3P (pep) (— △ —), with an irrelevant peptide (ipep) (— ● —), or without peptide (— △ —), and T2 cells were pulsed with ORF3P (— O —) as marked. After incubation, TIL586 was added and mixed with the target cells. Cytolytic activity of TIL586 was measured in a 4-h ⁵¹Cr release assay. (C) Titration of the peptide concentration to sensitize the target cells for lysis by TIL586. 586EBV cells were separately incubated with serial dilutions of ORF3P (pep) (— △ —) or irrelevant peptides (ipep) (— ● —) and T2 cells with the ORF3P peptide (— O —) for 90 min. The cytolytic activity of TIL586 was evaluated in a 4-h ⁵¹Cr release assay at an E/T ratio of 40:1.

---

B cells pulsed with the ORF3P peptide, and HLA-A31 positive melanocytes, but not 397mel/A31 + or 586EBV B cells alone. Representative data are shown in Fig. 6. These results suggested that T cell clones probably recognized a naturally processed peptide either similar or identical to the ORF3P peptide on tumor cells and normal melanocytes.

Since there is a 40–45% amino acid sequence identity of gp75 to tyrosinase, gp100, and TRP-2, we tested the possibility that the peptide recognized by the T cell clones was not derived from gp75, but from one of these other proteins. We thus transfected COS-7 cells with HLA-A31 plus either tyrosinase, gp100, or TRP-2 cDNAs, and found that none could be recognized by the six T cell clones, whereas the COS-7-transfected HLA-A31 and gp75 cDNA stimulated GM-CSF release from these clones (data not shown). A computer database search also indicated that no known proteins, including tyrosinase, gp100, and TRP-2, in the available database contained amino acid sequences with the peptide-binding motif of HLA-A31 and significant similarity to the peptide epitope recognized by TIL586.
### Table 2. Identification of Antigenic Peptides with Reactivity to TIL586

| Target cells pulsed with peptide | GM-CSF release | Percent specific lysis (E/T ratio 20:1) |
|---------------------------------|----------------|----------------------------------------|
| **Experiment A**                |                |                                        |
| Peptides derived from ORF2       |                |                                        |
| 586EBV + peptide ISQDTTVGR      | <50            | <10                                    |
| 586EBV + peptide AISQDTTVGR     | <50            | <10                                    |
| 586EBV + peptide AGEELPVTTR     | <50            | <10                                    |
| Peptides derived from ORF3       |                |                                        |
| 586EBV + peptide LWDVPSWLER     | <50            | <10                                    |
| 586EBV + peptide MSLQRQFLR      | >8,000         | 60                                     |
| 586EBV + none                   | <50            | <10                                    |
| 586mel + none                   | >5,000         | 47                                     |
| **Experiment B**                |                |                                        |
| Modified peptides of MSLQRQFLR  |                |                                        |
| 586EBV + peptide MSLQRQFLR      | >8,000         | 63                                     |
| 586EBV + peptide MSLQRQFLRT     | <50            | <10                                    |
| 586EBV + peptide SLQRQFLRT      | <50            | <10                                    |
| 586EBV + peptide MALQRQFLR      | >5,000         | 54                                     |
| 586EBV + peptide MLLQRQFLR      | <50            | <10                                    |
| 586EBV + peptide MRLQRQFLR      | <50            | <10                                    |
| 586EBV + peptide MSLQRQFLR      | <50            | <10                                    |
| 586EBV + peptide MSLQRQFLIK     | <50            | <10                                    |
| 586EBV + none                   | <50            | <10                                    |
| 586mel + none                   | >5,000         | 48                                     |

Conditions for peptide incubation with 586EBV B cells and GM-CSF release assay were the same as described in Table 1. GM-CSF secretion by TIL586 alone without stimulators was subtracted. Modified peptides were made by substitution of amino acid at positions 2, 6, and 9 relative to MSLQRQFLR. Cytotoxic lysis of peptide-pulsed 586EBV by TIL586 was done in a 4-h 51Cr release assay.

Oxognition with a natural peptide on tumor cells. However, we could not exclude the possibility that these T cells may cross-react with another peptide derived from a distinct protein on tumor cells and melanocytes, since we have not directly isolated the ORF3P peptide from tumor cells.

It was reported that T cell-epitope peptides derived from the frameshift of the mutated adenomatosis polyposis coli gene in colon cancer were recognized by CTLs generated from vaccinated BALB/c mice (28). The results shown in Fig. 3 indicated that the ATG at nucleotides 294–296 was required for translation of the 24-amino acid product, which, in turn, was processed to the antigenic peptide recognized by TIL586. TIL586 still recognized the mutated synthetic peptide pulsed on 586EBV B cells, but not the mutated gene when cotransfected into COS-7 cells with HLA-A31 cDNA, indicating that the loss of recognition of the mutated (ATG to ATC) gene by TIL586 resulted from elimination of translation of the ORF3 product. These results plus DNA sequence analysis ruled out the possibility that the antigenic peptide recognized by TIL586 was derived from the frameshift product of gp75. It is possible, therefore, that multiple peptides or proteins are often translated from overlapping open reading frames of a single eukaryotic gene, but that means to detect these alternate products have not been available. The exquisite sensitivity of T cells which can detect naturally processed peptides may allow one to reveal many other examples of this phenomenon.

The mechanism by which the overlapping ORF3 is translated is currently unclear. Although examples have been reported of cellular mRNAs that initiate at more than one AUG codon (29, 30), and that, in some rare cases, initiate at both AUG and non-AUG codons such as CUG to generate NH2-terminally extended identical sequences (21, 23), the use of overlapping open reading frames (i.e., translating two completely dissimilar peptides) from a single eukaryotic cellular mRNA has to our knowledge never been described. Several examples of translation of overlapping open reading frames from a single mRNA have been described, but they are exclusively limited to viral genes (31–34). The detection of the products of overlapping open reading frames in viral genes has been possible because of the existence of reactive antibodies in the sera of virally infected
hosts. In our case, we used a T cell assay to identify the epitope peptide recognized by T cells. This approach is very different from and more sensitive than conventional Western blots or immunoprecipitation analyses (35). Although there are five ATG codons between the authentic start codon of gp75 protein and the start codon of ORF3, the construct pCR110 covering the NH2-terminal part of ORF1 (gp75) and the entire ORF2 and ORF3 (nucleotides 1-667) still retained the ability to stimulate cytokine release from TIL586. The level of stimulation by pCR110, however, was severalfold lower than that stimulated by the 5' truncated (lacking the first 246 nucleotides) form of gp75 (Fig. 1, A and B), suggesting that the upstream ATG codons may have partially inhibited the expression of ORF3. Several factors have made it possible to detect the expression of the ORF3 product in this system. First, the upstream ATG codons preceding the ATG start codon of ORF3 did not appear to be in the optimal context, which may allow use of the downstream ATG as start codons by the leaky scanning model. Second, the relatively high expression of transfected genes in COS-7 cells and the availability of the T cell assay as an extremely sensitive means may allow us to detect very low levels of the translated products.

Interestingly, the ORF3 product was detected by T cells in the tumor cells as well as normal melanocytes (Fig. 6), strongly suggesting that the ORF3 protein was not a gene product resulting from genetic alterations in tumor cells. In previous studies, it was shown that TIL586 recognized multiple tumor cell lines (gp75+/A31+) tested, suggesting that TIL586 recognizes a nonmutated, shared tumor antigen (18). Since the gp75 gene is highly expressed in melanomas based on Northern blot and PCR analyses (18), and its gene product gp75 protein is the most abundant intracellular glycoprotein expressed in melanoma cells and melanocytes (36-38), it is not surprising that the T cell clones recognized the ORF3P peptide when pulsed onto 586EBV B cells (A31+), and also recognized melanoma (gp75+/A31+) as well as A31+ melanocytes, but not gp75-/A31- melanoma cells or ORF3P pulsed on non-A31 T2 cells. Another possibility to explain the peptide expression in tumor cells and melanocytes is that ORF3 may be translated from a separate mRNA transcript(s) generated by an alternative splicing of gp75 mRNA or a different promoter. To our knowledge, mRNA transcripts generated by alternative splicing are translated into isoform proteins by use of the same open reading frames. In our case, however, a separate transcript may be generated and used as a template for trans-s
lation, but a completely different open reading frame relative to gp75 was used to translate the ORF3 product. The complete structural organization of gp75 is presently unknown. Further experiments are needed to clarify the mechanisms for the translation of the ORF3 protein. Nevertheless, the possibilities mentioned above are not mutually exclusive.

Several years ago, the pepton hypothesis was proposed by Boon and Van Pel (39) to explain the observation that a short piece of promoterless subgenic DNA fragments transfected into P1 tumor cells directed the synthesis and surface expression of P91A tumr antigen. This hypothesis, however, requires an unidentified new RNA polymerase and other factors to direct transcription and states that peptons are expressed in all tissues (39, 40). Although the pepton hypothesis explains a surprising observation, it fails to explain how an alternative open reading frame was translated from gp75 mRNA, and the tissue specificity of this gene expression. The gp75 gene expression requires a classic RNA polymerase II promoter such as CMV promoter and the normal gp75 promoter.

In summary, the gp75 gene encodes two gene products, the 24-amino acid peptide of ORF3, which was processed to an antigenic peptide recognized by T cells, and the gp75 protein, which was previously identified as an antigen by IgG antibodies in the sera from a patient with melanoma. The infusion of TILS86 plus IL-2 into an autologous patient with metastatic melanoma resulted in the objective regression of tumor (17). These results suggest that the MSLQRQFLR peptide derived from ORF3 and recognized by TILS86 is a tumor rejection antigen. The products of this gene may be promising candidates for developing immunotherapeutic strategies for the treatment of patients with melanoma.

We thank Drs. S. Topalian and J.R. Yannelli for providing cell lines. X. Kang for helpful discussions, and L. Rivoltini for technical advice on T cell cloning. We also thank A. Mixon and E.B. Fitzgerald for FACS® analysis.

Address correspondence to Dr. Steven A. Rosenberg, Building 10, 2B42, National Cancer Institute, NIH, Bethesda, MD 20892-1502.

Received for publication 29 August 1995 and in revised form 2 November 1995.

Note added in proof: The use of alternative open reading frames for translating two gene products, p16INK4a and p19ARF, from the p16 tumor suppressor gene has recently been reported (41).

References

1. Rosenberg, S.A., B.S. Packard, P.M. Aebersold, D. Solomon, S.L. Topalian, S.T. Toy, P. Simon, M.T. Lotze, J.C. Yang, C.A. Seipp, et al. 1988. Use of tumor infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. Preliminary report. N. Engl. J. Med. 319:1676–1680.

2. Rosenberg, S.A., J.Y. Yannelli, and J.C. Yang. 1994. Treatment of patients with metastatic melanoma using autologous tumor-infiltrating lymphocytes and interleukin-2. J. Natl. Cancer Inst. 86:1159–1166.

3. Boon, T., J.-C. Cerottini, B. Van Den Eynde, P. Van der Bruggen, and A. Van Pel. 1994. Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol. 12:337–365.

4. Houghton, A.N. 1994. Cancer antigens: immune recognition of self and altered self. J. Exp. Med. 180:1–4.

5. Tsomides, T.J., and H.N. Eisen. 1994. Commentary: T-cell antigens in cancer. Proc. Natl. Acad. Sci. USA. 91:3487–3489.

6. Pardoll, D.M. 1994. News and views: a new look for the 1990s. Nature (Lond.). 369:357–358.

7. Rosenberg, S.A. 1995. Development of new cancer therapeutics based on the molecular identification of cancer regression antigens. The Cancer Journal from Scientific American 1:90–100.

8. Van der Bruggen, P., C. Traversari, P. Chomez, C. Lurquin, E. DePlaen, B. Van Den Eynde, A. Knuth, and T. Boon. 1991. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science (Wash. DC). 254:1643–1647.

9. Gaugler, B., B. Van Den Eynde, P. Van der Bruggen, P. Romero, J.J. Gaforio, E. De Plaen, B. Lethe, F. Brasseur, and T. Boon. 1994. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J. Exp. Med. 179:921–930.

10. Boel, P., C. Wildmann, M.I. Sensi, R. Brasseur, J.C. Renaud, P. Coulie, T. Boon, and P. Van der Bruggen. 1995. BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity. 2:167–175.

11. Brichard, V., A. Van Pel, T. Wolfel, C. Wolfel, E. De Plaen, B. Lethe, P. Coulie, and T. Boon. 1993. The tyrosinase gene codes for an antigen recognized by autologous T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 178:489–495.

12. Robbins, P.F., M. El-Gamil, Y. Kawakami, E. Stevens, J. Yannelli, and S.A. Rosenberg. 1994. Recognition of tyrosinase by tumor infiltrating lymphocytes from a patient responding to immunotherapy. Cancer Res. 54:3124–3126.

13. Kawakami, Y., S. Eliyahu, C.H. Delgado, P.F. Robbins, L. Rivoltini, S.L. Topalian, T. Miki, and S.A. Rosenberg. 1994. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. Natl. Acad. Sci. USA. 91:3515–3519.

14. Coulie, P.G., V. Brichard, A. Van Pel, T. Wolfel, J. Schneider, C. Traversari, S. Mattei, E.D. De Plaen, C.
Lurquin, J.-P. Szikora, et al. 1994. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 180:35-42.

15. Bakker, A.B.H., M.W.J. Schreurs, A.J. de Boer, Y. Kawakami, S.A. Rosenberg, G.J. Adema, and C.G. Fidger. 1994. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J. Exp. Med. 179:1005-1009.

16. Kawakami, Y., S. Eliyahu, C.H. Delgado, P.F. Robbins, K. Sakaguchi, E. Appella, J.R. Yannelli, G.J. Adema, T.M. Miki, and S.A. Rosenberg. 1994. Identification of a human melanoma antigen recognized by tumor infiltrating lymphocytes associated with in vivo tumor rejection. Proc. Natl. Acad. Sci. USA. 91:6458-6462.

17. Topalian, S., D. Solomon, F.P. Avis, A.E. Chang, D.L. Freeksen, W.M. Linehan, M.T. Lorze, C.N. Robertson, C.A. Seipp, and P. Simon, et al. 1988. Immunotherapy of patients with advanced cancer using tumor infiltrating lymphocytes and recombinant interleukin-2: a pilot study. J. Clin. Oncol. 6:839-853.

18. Wang, R.F., P.F. Robbins, Y. Kawakami, X.-Q. Kang, and S.A. Rosenberg. 1995. Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes. J. Exp. Med. 181:799-804.

19. Mattes, M.J., T.M. Thomson, L.J. Old, and K.O. Lloyd. 1983. A pigmentation-associated differentiation antigen of human melanoma defined by a precipitating antibody in human serum. Int. J. Cancer. 32:717-721.

20. Vijayasyradhi, S., B.B. Bouchard, and A.N. Houghton. 1990. The melanoma antigen gp75 is the human homologue of mouse b (brown) locus gene. J. Exp. Med. 171:1375-1380.

21. Kozak, M. 1989. The scanning model for translation: an update. J. Cell Biol. 108:229-241.

22. Hann, S.R. 1994. Regulation and function of non-AUG initiation codons: effects on regulation of synthesis and biological activity. J. Virol. 68:170-176.

23. Muralidhar, S., S.P. Becerra, and J.A. Rose. 1994. Site-directed mutagenesis of adenovirus type 2 structural proteins: generation of linked transcription and translation of short subgenic regions. A hypothesis. J. Cell Biol. 120:207-219.

24. IIyama, Y., S. Eliyahu, K. Sakaguchi, P.F. Robbins, L. Rivoltini, J.B. Yannelli, E. Appella, and S.A. Rosenberg. 1994. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J. Exp. Med. 180:347-352.

27. Cox, A.L., J. Skipper, Y. Cohn, R.A. Henderson, T.L. Dar-